Agents and methods for treating pancreatic ductal adenocarcinomas
US10588920B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2016 |
| Grant date | Mar 17, 2020 |
| Priority date | — |
| Expiry date | Apr 23, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/98
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.